The prospective imposition of tariffs on pharmaceutical imports by the Trump administration poses a significant challenge for the Indian pharmaceutical sector. Tariffs can increase the cost of imported goods, impacting profitability and competitiveness. For the Indian pharma industry, this could lead to reduced export volumes to the US and potentially hinder growth. Investors in pharmaceutical companies with significant exposure to the US market should monitor these developments closely. Trade policies and international relations between the US and India are critical political and economic factors that will determine the actual impact.